SCHEMBL2179719

SCHEMBL2179719

CC(C)[C@@H](C(=O)O)N1Cc2ccc(-c3ccc(NS(=O)(=O)c4ccc(F)c(F)c4)cc3)cc2C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.41
GFER P55789 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
PRF1 P14222 1/20 0.41
MAPT P10636 3/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
DRD2 P14416 1/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
DRD3 P35462 1/20 0.40
HTR6 P50406 1/20 0.40
KIT P10721 1/20 0.39
SDCBP O00560 4/20 0.39
SDC2 P34741 4/20 0.39
HTT P42858 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
ACLY P53396 1/20 0.38
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2179136 1.00 LMNA (0.41) LMNAGFERSMN1; SMN2PRF1MAPT
SCHEMBL2178685 0.93 PRF1 (0.48) LMNAGFERSMN1; SMN2PRF1MAPT
SCHEMBL2180412 0.93 PRF1 (0.48) LMNAGFERSMN1; SMN2PRF1MAPT
SCHEMBL2179343 0.88 SDCBP (0.47) LMNASDCBPSDC2THRB
SCHEMBL2181348 0.88 SDCBP (0.47) LMNASDCBPSDC2THRB
SCHEMBL2178580 0.87 MMP13 (0.47) LMNAMEN1KMT2AKITSDCBP
SCHEMBL2180298 0.87 PGR (0.51) LMNAPRF1MAPTSDCBPSDC2
SCHEMBL2182303 0.87 MMP13 (0.47) LMNAMEN1KMT2AKITSDCBP
SCHEMBL2180953 0.87 PGR (0.51) LMNAPRF1MAPTSDCBPSDC2
SCHEMBL2180411 0.86 MEN1 (0.47) LMNASMN1; SMN2PRF1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT LMNA 2193/4885GFER 1689/4885SMN1; SMN2 2783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.